GlobalData on MSN8h
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpointsAnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...
AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...
Zacks.com on MSN4h
AnaptysBio Stock Down as Eczema Study Fails to Meet GoalsPhase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.
AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...
AnaptysBio (ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses ...
Return on Equity (ROE): AnaptysBio's ROE is below industry averages, indicating potential challenges in efficiently utilizing ...
Its most advanced project is MB272, an agonist of B- and T-lymphocyte attenuator (BTLA) which recently started phase 1 testing, and it has a PD-1 agonist called MB151 in late preclinical development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback